Integrins: Signaling, disease, and therapy

International Journal of Radiation Biology

Volumn 83, Issue 11-12, 2007, Pages 743-751

  Huveneers, Stephan ^a   Truong, Hoa ^a   Danen, Erik H J ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adhesion; Cancer; Treatment

Indexed keywords

ABCIXIMAB; ALPHA6BETA4 INTEGRIN; ALPHA7 INTEGRIN; ANTIASTHMATIC AGENT; BACTERIAL POLYSACCHARIDE; CILENGITIDE; CONTORTROSTATIN; CYCLIN D1; CYCLIN E; EFALIZUMAB; EMD 12974; ENDOSTATIN; GEMCITABINE; INTEGRIN; LOTRAFIBAN; MITOGEN ACTIVATED PROTEIN KINASE; MLN 02; MONOCLONAL ANTIBODY LM 609; NATALIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RABTIVA; RESVERATROL; S 247; SB 273005; SC 55631; STRESS ACTIVATED PROTEIN KINASE; TR 14035; TRI 4035; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ASTHMA; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CORONARY ARTERY THROMBOSIS; CROHN DISEASE; CYTOSKELETON; DRUG TARGETING; ENTERITIS; EPIDERMOLYSIS BULLOSA; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; KERATINOCYTE; MUSCULAR DYSTROPHY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; UNSTABLE ANGINA PECTORIS;

ANIMALS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISINTEGRINS; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; NEOPLASMS; OLIGOPEPTIDES; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 36849048720     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000701481808     Document Type: Review

References (100)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE. 2005. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clinical Cancer Research 11:6270-6279.
2. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research 24:2783-2840.
3. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. 2006. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. International Journal of Radiation Oncology, Biology, Physics 65:1536-1543.
4. Allman R, Cowburn P, Mason M. 2000. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells. European Journal of Cancer 36:410-422.
5. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH. 2000. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. Journal of Cell Biology 149:741-754.
6. Assoian RK, Schwartz MA. 2001. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Current Opinion in Genetics & Development 11:48-53.
7. Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW. 2001. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis & Rheumatism 44:128-137.
8. Batt DG, Petraitis JJ, Houghton GC, Modi DP, Cain GA, Corjay MH, Mousa SA, Bouchard PJ, Forsythe MS, Harlow PP, Barbera FA, Spitz SM, Wexler RR, Jadhav PK. 2000. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3). Journal of Medicinal Chemistry 43:41-58.
9. Benaud CM, Dickson RB. 2001. Regulation of the expression of c-Myc by beta1 integrins in epithelial cells. Oncogene 20:759-768.
10. Bennett JS. 2001. Novel platelet inhibitors. Annual Review of Medicine 52:161-184.
11. Bokel C, Brown NH. 2002. Integrins in development: Moving on, responding to, and sticking to the extracellular matrix. Developmental Cell 3:311-321.
12. Borradori L, Sonnenberg A. 1999. Structure and function of hemidesmosomes: more than simple adhesion complexes. Journal of Investigative Dermatology 112:411-418.
13. Bouvard D, Brakebusch C, Gustafsson E, Aszodi A, Bengtsson T, Berna A, Fassler R. 2001. Functional consequences of integrin gene mutations in mice. Circulation Research 89:211-223.
14. Brooks PC, Clark RA, Cheresh DA. 1994a. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571.
15. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. 1994b. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
16. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. 1995. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. Journal of Clinical Investigation 96:1815-1822.
17. Burridge K, Chrzanowska-Wodnicka M. 1996. Focal adhesions, contractility, and signaling. Annual Review of Cell and Developmental Biology 12:463-518.
18. Cai W, Chen X. 2006. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anti-Cancer Agents in Medicinal Chemistry 6:407-428.
19. Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nature Reviews Cancer 1:118-129.
20. Chen Q, Lin TH, Der CJ, Juliano RL. 1996. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras [corrected]. Journal of Biological Chemistry 271:18122-18127.
21. Cheresh DA. 1987. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proceedings of the National Academy of Sciences USA 84:6471-6475.
22. Clark EA, Trikha M, Markland FS, Brugge JS. 1994. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. Journal of Biological Chemistry 269:21940-21943.
23. Colomer R. 2004. Gemcitabine and paclitaxel in metastatic breast cancer: A review. Oncology (Williston. Park) 18:8-12.
24. Cordes N. 2006. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. Cancer Letters 242:11-19.
25. Cortijo J, Sanz MJ, Iranzo A, Montesinos JL, Nabah YN, Alfon J, Gomez LA, Merlos M, Morcillo EJ. 2006. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. British Journal of Pharmacology 147:661-670.
26. Danen EH, Yamada KM. 2001. Fibronectin, integrins, and growth control. Journal of Cellular Physiology 189:1-13.
27. De Arcangelis A, Georges-Labouesse E. 2000. Integrin and ECM functions: Roles in vertebrate development. Trends in Genetics 16:389-395.
28. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H. 1999. N-Methylated cyclic RGD peptides as highly active and selective alpha(V) beta(3) integrin antagonists. Journal of Medicinal Chemistry 42:3033-3040.
29. Edwards GM, Wilford FH, Liu X, Hennighausen L, Djiane J, Streuli CH. 1998. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. Journal of Biological Chemistry 273:9495-9500.
30. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL. 1997. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation 99:2284-2292.
31. Evans RD, Perkins VC, Henry A, Stephens PE, Robinson MK, Watt FM. 2003. A tumor-associated beta 1 integrin mutation that abrogates epithelial differentiation control. Journal of Cell Biology 160:589-596.
32. Faham S, Linhardt RJ, Rees DC. 1998. Diversity does make a difference: fibroblast growth factor-heparin interactions. Current Opinion in Structural Biology 8:578-586.
33. Fassler R, Rohwedel J, Maltsev V, Bloch W, Lentini S, Guan K, Gullberg D, Hescheler J, Addicks K, Wobus AM. 1996. Differentiation and integrity of cardiac muscle cells are impaired in the absence of beta 1 integrin. Journal of Cell Science 109 (Pt 13):2989-2999.
34. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. 2005. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine 352:2499-2507.
35. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285:1182-1186.
36. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
37. Frisch SM, Screaton RA. 2001. Anoikis mechanisms. Current Opinion in Cell Biology 13:555-562.
38. Gardner JM, Hynes RO. 1985. Interaction of fibronectin with its receptor on platelets. Cell 42:439-448.
39. Geiger B, Bershadsky A, Pankov R, Yamada KM. 2001. Transmembrane crosstalk between the extracellular matrix - cytoskeleton crosstalk. Nature Reviews Molecular Cell Biology 2:793-805.
40. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. 2003. Natalizumab for active Crohn's disease. New England Journal of Medicine 348:24-32.
41. Giancotti FG, Ruoslahti E. 1999. Integrin signaling. Science 285:1028-1032.
42. Giavazzi R, Nicoletti MI. 2002. Small molecules in antiangiogenic therapy. Current Opinion in Investigational Drugs 3:482-491.
43. Gilcrease MZ. 2007. Integrin signaling in epithelial cells. Cancer Letters 247:1-25.
44. Goodman SL, Holzemann G, Sulyok GA, Kessler H. 2002. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. Journal of Medicinal Chemistry 45:1045-1051.
45. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, Niewiarowski S. 1990. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proceedings of the Society for Experimental Biology & Medicine 195:168-171.
46. Guo W, Giancotti FG. 2004. Integrin signalling during tumour progression. Nature Reviews Molecular Cell Biology 5:816-826.
47. Hartman GD, Duggan ME. 2000. alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption. Expert Opinion on Investigational Drugs 9:1281-1291.
48. Haskill S, Johnson C, Eierman D, Becker S, Warren K. 1988. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. Journal of Immunology 140:1690-1694.
49. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. 1999. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. Journal of Clinical Investigation 103:229-238.
50. Howe AK, Aplin AE, Juliano RL. 2002. Anchorage-dependent ERK signaling - mechanisms and consequences. Current Opinion in Genetics & Development 12:30-35.
51. Huang TF. 1998. What have snakes taught us about integrins? Cellular & Molecular Life Sciences 54:527-540.
52. Hynes RO. 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687.
53. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
54. Kerr JS, Slee AM, Mousa SA. 2000. Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opinion on Investigational Drugs 9:1271-1279.
55. Kim S, Bell K, Mousa SA, Varner JA. 2000. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. American Journal of Pathology 156:1345-1362.
56. Lakkakorpi PT, Helfrich MH, Horton MA, Vaananen HK. 1993. Spatial organization of microfilaments and vitronectin receptor, alpha v beta 3, in osteoclasts. A study using confocal laser scanning microscopy. Journal of Cell Science 104 (Pt 3):663-670.
57. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. 2003. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New England Journal of Medicine 349:2004-2013.
58. Lelievre SA, Weaver VM, Nickerson JA, Larabell CA, Bhaumik A, Petersen OW, Bissell MJ. 1998. Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus. Proceedings of the National Academy of Sciences USA 95:14711-14716.
59. Li ML, Aggeler J, Farson DA, Hatier C, Hassell J, Bissell MJ. 1987. Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells. Proceedings of the National Academy of Sciences USA 84:136-140.
60. Liddington RC, Ginsberg MH. 2002. Integrin activation takes shape. Journal of Cell Biology 158:833-839.
61. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S, Davis PJ. 2006. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB Journal 20:1742-1744.
62. Liu F, Craft RM, Morris SA, Carroll RC. 2000. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert Opinion on Investigational Drugs 9:2673-2687.
63. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. 2000. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Research 60:309-320.
64. Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA. 1999. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proceedings of the National Academy of Sciences USA 96:1591-1596.
65. Maniotis AJ, Chen CS, Ingber DE. 1997. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proceedings of the National Academy of Sciences USA 94:849-854.
66. McLane MA, Sanchez EE, Wong A, Paquette-Straub C, Perez JC. 2004. Disintegrins. Current Drug Targets - Cardiovascular & Haematological Disorders 4:327-355.
67. Menko AS, Boettiger D. 1987. Occupation of the extracellular matrix receptor, integrin, is a control point for myogenic differentiation. Cell 51:51-57.
68. Mikecz K. 2000. Vitaxin applied molecular evolution. Current Opinion in Investigational Drugs 1:199-203.
69. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 348:15-23.
70. Mizejewski GJ. 1999. Role of integrins in cancer: survey of expression patterns. Proceedings of the Society for Experimental Biology & Medicine 222:124-138.
71. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
72. Pierschbacher MD, Ruoslahti E. 1984. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30-33.
73. Pitts WJ, Wityak J, Smallheer JM, Tobin AE, Jetter JW, Buynitsky JS, Harlow PP, Solomon KA, Corjay MH, Mousa SA, Wexler RR, Jadhav PK. 2000. Isoxazolines as potent antagonists of the integrin alpha(v)beta(3). Journal of Medicinal Chemistry 43:27-40.
74. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. 1985. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proceedings of the National Academy of Sciences USA 82:8057-8061.
75. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. 2001. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biotherapy & Radiopharmaceuticals 16:125-132.
76. Rader C, Popkov M, Neves JA, Barbas CF III. 2002. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB Journal 16:2000-2002.
77. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. 2004. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncology 40:228-230.
78. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. 2003. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Research 63:2079-2087.
79. Renshaw MW, Ren XD, Schwartz MA. 1997. Growth factor activation of MAP kinase requires cell adhesion. EMBO Journal 16:5592-5599.
80. Rohwedel J, Guan K, Zuschratter W, Jin S, Hnert-Hilger G, Furst D, Fassler R, Wobus AM. 1998. Loss of beta1 integrin function results in a retardation of myogenic, but an acceleration of neuronal, differentiation of embryonic stem cells in vitro. Developmental Biology 201:167-184.
81. Ruoslahti E. 1996. RGD and other recognition sequences for integrins. Annual Review of Cell & Developmental Biology 12:697-715.
82. Schlaepfer DD, Hunter T. 1998. Integrin signalling and tyrosine phosphorylation: Just the FAKs? Trends in Cell Biology 8:151-157.
83. Shattil SJ. 2005. Integrins and Src: Dynamic duo of adhesion signaling. Trends in Cell Biology 15:399-403.
84. Shi C, Simon DI. 2006. Integrin signals, transcription factors, and monocyte differentiation. Trends in Cardiovascular Medicine 16:146-152.
85. Shimaoka M, Springer TA. 2003. Therapeutic antagonists and conformational regulation of integrin function. Nature Reviews Drug Discovery 2:703-716.
86. Sircar I, Gudmundsson KS, Martin R, Liang J, Nomura S, Jayakumar H, Teegarden BR, Nowlin DM, Cardarelli PM, Mah JR, Connell S, Griffith RC, Lazarides E. 2002. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: Discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist. Bioorganic & Medicinal Chemistry 10:2051-2066.
87. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM. 2003. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. International Journal of Cancer 104:496-503.
88. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. 2001. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. Journal of Cell Biology 155:459-470.
89. Swenson S, Costa F, Ernst W, Fujii G, Markland FS. 2005. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiology of Haemostasis and Thrombosis 34:169-176.
90. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE. 2002. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. International Journal of Cancer 98:690-697.
91. Teicher BA. 1996. A systems approach to cancer therapy. (Antioncogenics+standard cytotoxics ->mechanism(s) of interaction). Cancer and Metastasis Reviews 15:247-272.
92. Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS. 1994. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thrombosis Research 73:39-52.
93. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. 2002. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Research 62:2824-2833.
94. Vachon PH, Xu H, Liu L, Loechel F, Hayashi Y, Arahata K, Reed JC, Wewer UM, Engvall E. 1997. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy. Journal of Clinical Investigation 100:1870-1881.
95. van der Flier A, Sonnenberg A. 2001. Function and interactions of integrins. Cell & Tissue Research 305:285-298.
96. Varner JA, Emerson DA, Juliano RL. 1995. Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Molecular Biology of the Cell 6:725-740.
97. Watt FM. 2002. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO Journal 21:3919-3926.
98. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. 2002. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2:205-216.
99. Wu AM, Senter PD. 2005. Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnology 23:1137-1146.
100. Yamada KM, Even-Ram S. 2002. Integrin regulation of growth factor receptors. Nature Cell Biology 4:E75-76.